FDA Approves Xtandi for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

The FDA approved enzalutamide (Xtandi, Astellas Pharma) for nonmetastatic castration-sensitive prostate cancer ...

NOVEMBER 21, 2023